JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Audinot, V.
Right arrow Articles by Millan, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Audinot, V.
Right arrow Articles by Millan, M. J.

Vol. 287, Issue 1, 187-197, October 1998

A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194

Valérie Audinot, Adrian Newman-Tancredi, Alain Gobert, Jean-Michel Rivet, Mauricette Brocco, Françoise Lejeune, Laurence Gluck, Isabelle Desposte, Karin Bervoets, Anne Dekeyne and Mark J. Millan

Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, Paris, France

The benzofurane (+)-S 14297, the benzamide nafadotride, the aminoindane U 99194 and the arylpiperazine GR 103,691 have been proposed as "selective" antagonists at dopamine D3 vs. D2 receptors. Herein, we compared their in vitro affinities and in vivo actions to those of the aminotetralin D3 antagonists (+)-AJ 76 and (+)-UH 232. Affinities at recombinant, human (h)D3 and/or hD2 sites were determined by employing the mixed D2/D3 antagonist [125I]-iodosulpride and the preferential D3 ligands [3H]-(+)-PD 128,907 and [3H]-(+)-S 14297. [3H]-(+)-PD 128,907, [3H]-(+)-S 14297 and [125I]-iodosulpride yielded an essentially identical pattern of displacement at D3 sites, which suggests that they recognize the same population of receptors. The rank order of potency (Ki values in nM vs. [3H]-(+)-PD 128,907) was GR 103,691 (0.4) approx  nafadotride (0.5) > haloperidol (2) approx  (+)-UH 232 (3) approx  (+)-S 14297 (5) > (+)-AJ 76 (26) > U 99194 (160). The rank order of preference (Ki ratio, D2:D3) for D3 receptors (labeled by [3H]-PD 128,907) vs. D2 sites (labeled by [125I]-iodosulpride) was (+)-S 14297 (61) approx  GR 103,691 (60) > U 99194 (14) > nafadotride (9) approx  (+)-UH 232 (8) approx  (+)-AJ 76 (6) > haloperidol (0.2). (+)-S 14297 and GR 103,691 also showed greater than 100-fold selectivity at dopamine hD3 vs. hD4 and hD1 sites. However, GR 103,691 showed marked affinity for serotonin1A receptors (5.8 nM) and alpha-1 adrenoceptors (12.6 nM). In vivo, all antagonists except GR 103,691 prevented the induction of hypothermia by (+)-PD 128,907 (0.63 mg/kg s.c.) and a further preferential D3 agonist, (+)-7-OH-DPAT (0.16 mg/kg s.c.). On the other hand, haloperidol, (+)-AJ 76, (+)-UH 232 and nafadotride all induced catalepsy in rats, whereas (+)-S 14297, U 99194 and GR 103,691 were inactive. Haloperidol, (+)-AJ 76, (+)-UH 232, nafadotride and (weakly) U 99194 also enhanced prolactin secretion and striatal dopamine synthesis, whereas (+)-S 14297 and GR 103,691 were inactive. However, despite its high affinity at 5-HT1A receptors and alpha-1 adrenoceptors, both of which are present on raphe-localized serotonergic neurons, GR 103,691 (0.5 mg/kg i.v.) failed to influence their basal firing rate or the inhibition of their electrical activity by the 5-HT1A agonist (±)-8-OH-DPAT (0.005 mg/kg i.v.), a result that casts doubt on its activity in vivo. In conclusion, both (+)-S 14297 and GR 103,691 are markedly selective ligands that permit the characterization of actions at hD3 vs. hD2 receptors in vitro, but (+)-S 14297 appears to be of greater utility for the evaluation of their functional significance in vivo. Nevertheless, to develop a better understanding of the respective roles of dopamine D3 and D2 receptors, we need additional, chemically diverse antagonists of improved potency and selectivity.

0022-3565/98/2871-0187$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
G. Chen, J. T. Kittler, S. J. Moss, and Z. Yan
Dopamine D3 Receptors Regulate GABAA Receptor Function through a Phospho-Dependent Endocytosis Mechanism in Nucleus Accumbens
J. Neurosci., March 1, 2006; 26(9): 2513 - 2521.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Jeanblanc, D.-Y. He, N. N. H. McGough, M. L. Logrip, K. Phamluong, P. H. Janak, and D. Ron
The Dopamine D3 Receptor Is Part of a Homeostatic Pathway Regulating Ethanol Consumption
J. Neurosci., February 1, 2006; 26(5): 1457 - 1464.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Hammad and J. J. Wagner
Dopamine-Mediated Disinhibition in the CA1 Region of Rat Hippocampus via D3 Receptor Activation
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 113 - 120.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. T. Collins, J. M. Witkin, A. H. Newman, K. A. Svensson, P. Grundt, J. Cao, and J. H. Woods
Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 310 - 319.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. Clemens and S. Hochman
Conversion of the Modulatory Actions of Dopamine on Spinal Reflexes from Depression to Facilitation in D3 Receptor Knock-Out Mice
J. Neurosci., December 15, 2004; 24(50): 11337 - 11345.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Reavill, S. G. Taylor, M. D. Wood, T. Ashmeade, N. E. Austin, K. Y. Avenell, I. Boyfield, C. L. Branch, J. Cilia, M. C. Coldwell, et al.
Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1154 - 1165.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. R. Ashby Jr., Y. Minabe, G. Stemp, J. J. Hagan, and D. N. Middlemiss
Acute and Chronic Administration of the Selective D3 Receptor Antagonist SB-277011-A Alters Activity of Midbrain Dopamine Neurons in Rats: An In Vivo Electrophysiological Study
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1166 - 1174.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. V. Khroyan, R. L. Barrett-Larimore, J. K. Rowlett, and R. D. Spealman
Dopamine D1- and D2-Like Receptor Mechanisms in Relapse to Cocaine-Seeking Behavior: Effects of Selective Antagonists and Agonists
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 680 - 687.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Chu, T.-C. Chu, and D. E. Potter
Mechanisms and Sites of Ocular Action of 7-Hydroxy-2-dipropylaminotetralin: A Dopamine3 Receptor Agonist
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 710 - 716.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle
S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: I. Receptorial, Electrophysiological and Neurochemical Profile Compared with GR218,231 and L741,626
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1048 - 1062.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Dekeyne, J.-M. Rivet, T. Dubuffet, G. Lavielle, and M. Brocco
S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: II. Functional and Behavioral Profile Compared with GR218,231 and L741,626
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1063 - 1073.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Gobert, K. Bervoets, J.-M. Rivet, S. Veiga, and M. Brocco
Induction of Spontaneous Tail-Flicks in Rats by Blockade of Transmission at N-Methyl-D-Aspartate Receptors: Roles of Multiple Monoaminergic Receptors in Relation to the Actions of Antipsychotic Agents
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 672 - 683.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.